Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon
Cuiling Guo,Dandan Guo,Liu Fang,Tingting Sang,Jianjun Wu,Chengjie Guo,Yujie Wang,Ying Wang,Chaojie Chen,Jiajun Chen,Rong Chen,Xingya Wang
DOI: https://doi.org/10.1016/j.carbpol.2021.118231
IF: 10.723
2021-09-01
Carbohydrate Polymers
Abstract:<p>This study investigated the effects of water-soluble polysaccharide extracted from the sporoderm-removed spores of <em>Ganoderma lucidum</em> (GLP) against AOM/DSS-induced inflammation, tumorigenesis, and gut microbiota modification, which has never been reported before. Our data revealed that GLP (200 and 300 mg/kg) decreased AOM/DSS-induced colitis and tumorigenesis, manifested by significantly reduced disease activity index score, and total number and size of tumors. Furthermore, GLP ameliorated AOM/DSS-induced microbiota dysbiosis, increased short-chain fatty acid production, and alleviated endotoxemia by inhibiting TLR4/MyD88/NF-κB signaling. Besides, GLP profoundly improved gut barrier function as evidenced by increased numbers of goblet cells, MUC2 secretion, and tight junction protein expressions. GLP treatment inhibited macrophage infiltration and downregulated IL-1β, iNOS, and COX-2 expressions. Additionally, GLP inhibited lipopolysaccharides (LPS)-induced inflammation markers and MAPK (JNK and ERK) activation in macrophage RAW264.7, intestinal HT-29, and NCM460 cells. In conclusion, these results indicate that GLP is a promising prebiotic for the treatment of colorectal cancer.</p>
polymer science,chemistry, organic, applied